The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday.

The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the ...

The US Food and Drug Administration will now review Moderna’s new, messenger RNA–based flu vaccine after all, reversing course on a decision that rocked the biopharmaceutical industry last week.

The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu ...

Moderna announced that the FDA will review its new mRNA flu vaccine, a reversal less than two weeks after the agency refused to do so.

Greenville ISD is accepting applications for the 2026-2027 school year for Early College High School, offering incoming eighth-grade students the opportunity to earn a high school diploma ...

Moderna said after a "Type A" meeting, the agency agreed to move forward and review its application for the mRNA-based shot.

Moderna said on the FDA has agreed to review its influenza vaccine, reversing an earlier decision to reject the application.

Moderna said on Wednesday the U.S. drug regulator will review its modified flu vaccine application, a week after rejecting the original submission.

The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for ...

The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date.

The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA ...